This report is an ADVERTISEMENT from SafeHaven.com
Mark this date down: October 17th.
That’s the day that Canada fully legalizes recreational cannabis.
And that’s also the date that the best kept story in the cannabis sector
could be revealed.
A team that has already built two cannabis companies to a $340 million and
$5 billion valuation.
But now, they are involved with something that could become much bigger… Scythian
Biosciences (CSE:SCYB,
OTCMKTS:SCCYF)
So, what’s going on?
First, Scythian has just closed an incredible $280 million deal with
Aphria, the third-largest cannabis company in the world.
Aphria saw the potential in Scythian’s “cannabis incubator” investment
plans, and agreed to sell $193 million in stock to them… and today – as they
close the deal – that same stock is worth nearly $300 million.
That’s a $137 million windfall for Scythian… a 65 percent ROI. And
that’s only one deal of many.
Scythian Biosciences (CSE:SCYB, OTCMKTS:SCCYF)
story could blow the lid off the cannabis market. It’s already one of the biggest
investment trends of 2018.
Canada is instituting full legalization on October 17, and the Scythian
story is unlikely to stay off the radar for long when that happens.
Here are five things you need to know about Scythian…
#1 The Crucial Time is Now Because Canada Legalizes Recreational
Cannabis on October 17th
For decades, marijuana was off the grid: an estimated $53 billion American
market[i]
for an illegal substance without any kind of legitimate investment footprint.
Now, that’s changing. Canada is on the verge of instituting full
recreational legalization.
It’s all over the news, and it’s caused a huge spike in investor interest
in the cannabis sector… and it will probably only get bigger in the run up to
October 17th.
But what most people don’t know is that the marijuana sector isn’t getting
its backing from Wall Street, which struggles
to nail down the value of the legal cannabis market while illicit growers
are still in the game.
Instead, funding is coming from publicly traded companies acting as
incubators for promising cannabis ventures worldwide.
And Scythian Biosciences (CSE:SCYB,
OTCMKTS:SCCYF)
is the top incubator that anyone can invest in through their brokerage
account.
So, Scythian stock gives investors access to a huge potential upside
normally reserved for Venture Capital by offering the rare opportunity to buy
into dozens of companies before they hit the big time.
But mainstream investors haven’t caught on, probably because other
cannabis companies have been competing so fiercely for the cannabis
spotlight. And that’s opened up a big opportunity for investors to consider
Scythian’s value in comparison to cannabis high flyers before October 17th.
In a short span of time, the tiny legal cannabis sector is likely to
explode from near zero just a couple of years ago to $8.7 billion in sales by
2024. Worldwide, the cannabis market could reach $32 billion by 2022 and $57
billion by 2027.
Access to just a tiny sliver of that market could give Scythian a huge
upside.
#2 A $57 Billion Opportunity In Cannabis By 2027
Scythian Biosciences (CSE:SCYB, OTCMKTS:SCCYF) is an
international incubator of cannabis assets.
That makes it unique: most pot stocks, such as Aphria and Canopy Growth
Inc., focus on cultivation, production and marketing in one country.
Calculating an upside in those kinds of companies is relatively
straightforward, and in the case of Canopy most of the growth has
already been realized.
With an incubator, the upside could be enormous. One estimate has the
global cannabis market reaching
$65 billion by 2023.
And the most bullish estimate by British firm Bryan, Garnier & Co. has
legal pot sales reaching
$140 billion by 2027.
Any one of Scythian’s assets could explode on to the scene, especially at
a time when cannabis laws are changing all over the world at rapid speeds.
Scythian looks to invest in dozens of assets at an early stage, but it
only needs one asset to make it big to realize upside from the expected $57
billion or bigger global cannabis market.
Plus, it’s the first on the scene when it comes to pot incubation.
Wall Street is waiting for federal laws to loosen… so they are leery of
pot stocks, and Silicon Valley venture capital hasn’t picked up on it yet.
That leaves the field wide open for Scythian and other pot incubators to
get access to the best deals first.
More importantly, it has allowed early-in investors to get in on the
high-upside “early” investments normally reserved for Wall Street and Silicon
Valley.
#3 Incubating Dozens of Cannabis Companies of the Future
Scythian (CSE:SCYB,
OTCMKTS:SCCYF)
is a unique investment.
It…
- Has an Incubator business model that has so far resulted
in a high upside…
- Owns a highly diversified portfolio of cannabis assets,
ranging from North and South American to Western Europe…
- Has an experienced management team with multiple global
successes
- Has lower valuation than many cannabis companies…
- Is early-in to a brand new $8.7 billion market
Scythian’s “first mover” approach is to identify ideal assets in
undeveloped markets and incubate them for maximum profitability.
In Latin America… Scythian established relationships with “cultivation
hubs”, in a market which has over 600 million people, all potential pot
customers.
In North America, 90 percent of the pot market remains illegal… and yet
the market still generates more than $9 billion a year according
to ArcView Market Research. Legalization will let Scythian tap that
market and get around behemoths like Canopy Growth Corp.
The global legal cannabis market could be worth $57 billion in just a few
years, representing exponential growth.
And if Scythian captures just a tiny fraction of that potential, its
valuation should really please its shareholders.
#4 Management Team:
The executive team leading Scythian Biosciences (CSE:SCYB, OTCMKTS:SCCYF) has
been at the forefront of the biggest success stories in cannabis.
They were involved in Aphria, a cannabis giant that exploded into a $5
billion company. They are also some of the leading business figures in
the European cannabis industry.
But now they’re setting their sights on the high-upside incubator
business.
And Scythian’s world-class team is poised to take advantage of a colossal
new opportunity, one that could be worth hundreds of millions of dollars.
#5 Deal Closed, October 17th Approaching Fast
This deal between Aphria and Scythian Biosciences just closed, so the
market is still catching up to the news.
Here’s what happened: Aphria chose to buy into Scythian, pumping it full
of fresh capital for its incubation projects.
In July, Aphria announced plans to buy into Scythian, hoping to acquire a
number of Scythian’s Latin America and Caribbean assets for $193 million
payable mainly in Aphria stock.
Now, that Aphria stock position is worth more: $280 million on last count,
an increase of 79 percent.
Since announcing the news, Scythian’s stock has been climbing.
But this isn’t the only deal Scythian’s working on. They have dozens
of deals in the “incubator” pipeline… that Scythian plans to invest in,
incubate and bring to maturity and better valuations.
It’s taking
on an interest in Florida-based medical cannabis firm 3 Boys Farms LLC,
which will give it access to the Florida pot market when that state embraces
legalization. The company has announced its new
U.S. headquarters will be in Fort Lauderdale, Florida.
The acquisition is Scythian’s first big step into the North American
market, part of its plan to shift its attention towards specific cannabis
friendly zones in the United States.
The Aphria deal may be just the beginning. Scythian has its sights set on
U.S. expansion, branching out from its start in South America to embrace
North America.
The news is out there. It’s only a matter of time before this little firm
— with some of the team behind Red Bull — starts to attract even more
attention.
And, so far, the company has been hard at work executing their playbook.
Expect the market to start paying attention after recreational marijuana
is sold legally in Canada on October 17th.
When full legalization goes through, interest in cannabis stocks could
soar.
And Scythian Biosciences (CSE:SCYB,
OTCMKTS:SCCYF)
shareholders will get a piece of this growing
cannabis market… through an early mover that keeps stacking up success
upon success.
By. Ian Jenkins
i.
https://www.huffingtonpost.com/entry/legal-cannabis-industry-growth-2016-marijuana_us_587e785be4b0cf0ae88070c0
**IMPORTANT! BY READING OUR CONTENT YOU EXPLICITLY AGREE TO THE
FOLLOWING. PLEASE READ CAREFULLY**
Notice for Forward-Looking Information
Certain statements in this press release are forward-looking statements
and are prospective in nature. Forward-looking statements are not based on
historical facts, but rather on current expectations and projections about future
events, and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results expressed
or implied by the forward-looking statements. Such forward-looking
information includes that investor interest in the cannabis sector will
continue to grow to October 17, 2018 and beyond; that cannabis use and sales
will grow as currently predicted; Scythian Biosciences’ intended acquisition
of various foreign companies and expansion into the US market; that the
Aphria stock owned by Scythian Biosciences will retain its current
value and that Scythian Biosciences can realize a profit on its sale;
Scythian Biosciences’ plans to incubate projects in various locations
throughout the world; that it could be granted licensable patents; that
Scythian Biosciences will get an exclusive cannabis distribution license in
Florida; and that it will be able to carry out its business plans.
Readers are cautioned to not place undue reliance on forward-looking
information. Forward looking information is subject to a number of risks and
uncertainties that may cause actual results or events to differ materially
from those contemplated in the forward-looking information, and even if such
actual results or events are realized or substantially realized, there can be
no assurance that they will have the expected consequences to, or effects on
Scythian Biosciences. Such risks and uncertainties include, among other
things: that a regulatory approval that may be required for the intended
acquisitions and subsequent sales are not obtained or are obtained subject to
conditions that are not anticipated; growing competition for intended
acquisitions in the cannabis industry; potential future competition in the
markets Scythian Biosciences operates for sales; competitors may quickly
enter the industry; general economic conditions in the US, Canada and
globally; the inability to secure financing necessary to carry out its
business plans; competition for, among other things, capital and skilled
personnel; the possibility that government policies or laws may not permit
legal cannabis sales or growth or that favorable laws in place may change;
Scythian Biosciences not adequately protecting its intellectual property;
interruption or failure of information technology systems; the cannabis
market may not grow as expected; Scythian Biosciences’ technology may not
achieve the expected results and its accomplishments may be limited; Florida
may not grant to Scythian Biosciences an exclusive cannabis medical license;
even if it is granted the Florida license, Scythian Biosciences’ may not be
able to profitably use it; Scythian Biosciences’ business plan also
carries risk, including its ability to comply with all applicable
governmental regulations in a highly regulated business; incubator risk
investing in target companies or projects which have limited or no operating
history and are engaged in activities currently considered illegal under US
federal laws; and regulatory risks relating to Scythian Biosciences’
business, financings and strategic acquisitions.
DISCLAIMERS
PAID ADVERTISEMENT. This communication is a paid advertisement and is
not a recommendation to buy or sell securities. Safehaven.com, Advanced Media
Solutions Ltd, and their owners, managers, employees, and assigns
(collectively “the Company”) has been paid by the profiled company or a third
party to disseminate this communication. In this case the Company has been
paid by Scythian Biosciences seventy thousand US dollars for this article and
certain banner ads. This compensation is a major conflict with our ability to
be unbiased, more specifically:
This communication is for entertainment purposes only. Never invest purely
based on our communication. Gains mentioned in our newsletter and on our
website may be based on end-of- day or intraday data. We have been
compensated by Scythian Biosciences to conduct investor awareness advertising
and marketing for Scythian Biosciences’. Therefore, this communication should
be viewed as a commercial advertisement only. We have not investigated the
background of the company. The third party, profiled company, or their
affiliates may liquidate shares of the profiled company at or near the time
you receive this communication, which has the potential to hurt share prices.
Frequently companies profiled in our alerts experience a large increase in
volume and share price during the course of investor awareness marketing,
which often end as soon as the investor awareness marketing ceases. The
investor awareness marketing may be as brief as one day, after which a large
decrease in volume and share price is likely to occur.
We do not guarantee the timeliness, accuracy, or completeness of the
information on our site or in our newsletters. The information in our communications
and on our website is believed to be accurate and correct, but has not been
independently verified and is not guaranteed to be correct. The information
is collected from public and non-public sources but is not researched or
verified in any way whatsoever to ensure the information is correct.
SHARE OWNERSHIP. The owner of Safehaven.com owns shares
and/or stock options of this featured company and therefore has an additional
incentive to see the featured company’s stock perform well. The owner of Safehaven.com
will not notify the market when it decides to buy or sell shares of this
issuer in the market. The owner of Safehaven.com will be buying and selling
shares of the featured company for its own profit. This is why we stress that
you conduct extensive due diligence as well as seek the advice of your
financial advisor or a registered broker-dealer before investing in any
securities.
NOT AN INVESTMENT ADVISOR. The Company is not
registered or licensed by any governing body in any jurisdiction to give
investing advice or provide investment recommendation. ALWAYS DO YOUR OWN
RESEARCH and consult with a licensed investment professional before making an
investment. This communication should not be used as a basis for making any
investment.
INDEMNIFICATION/RELEASE OF LIABILITY. By reading
this communication, you agree to the terms of this disclaimer, including, but
not limited to: releasing The Company, its affiliates, assigns and successors
from any and all liability, damages, and injury from the information
contained in this communication. You further warrant that you are solely
responsible for any financial outcome that may come from your investment
decisions.
RISK OF INVESTING. Investing is inherently risky.
While a potential for rewards exists, by investing, you are putting yourself
at risk. You must be aware of the risks and be willing to accept them in
order to invest in any type of security. Don’t trade with money you can’t afford
to lose. This is neither a solicitation nor an offer to Buy/Sell securities.
SHTFplan Legal Notice: The content in this
article is provided by SHTFplan.com as general information only. The ideas
expressed herein are solely the opinions of the author(s) and do not
necessarily represent the opinions of sponsors or firms affiliated with the
author(s). Members of the SHTFplan.com staff and/or owners of SHTFplan.com
currently own no shares in the company mentioned. We will not purchase shares
in the next 30 days. SHTFplan.com has been compensated for a two week
marketing campaign. We were paid directly by SafeHaven.com, a third party
media company. Any action taken as a result of information, analysis, or
advertisement on this site is ultimately the responsibility of the reader.
The information herein is not intended to be personal legal or investment
advice and may not be appropriate or applicable for all readers. If personal
advice is needed, the services of a qualified legal, investment or tax
professional should be sought. Never base any decision on a single email. The
companies mentioned in this post are intended to be a stock ideas, NOT
recommendations. The ideas we present are high risk and you can lose your
entire investment. We are not stock pickers, market timers, investment
advisers, and you should not base any investment decision on our website,
emails, videos, or other published material. Please do your own research
before investing. It is crucial that you at least look at current SEC filings
and read the latest press releases. Information contained in this profile was
extracted from current documents filed with the SEC, the company web site and
other publicly available sources deemed reliable. Our report is not intended
to be, nor should it be construed as an offer to buy or sell, or a
solicitation of an offer to buy or sell securities, or as a recommendation to
purchase anything. This publication may provide the addresses or contain
hyperlinks to websites; we disclaim any responsibility for the content of any
such other websites.